Pieter H. Reitsma

Pieter H. Reitsma

Health Technology

Profile

Pieter H.
Reitsma was the founder of VarmX BV and held the title of Chief Scientific Officer, although he was not previously active in this role.

Former positions of Pieter H. Reitsma

CompaniesPositionEnd
Varmx BV
Logo Varmx BV

Varmx BV

BiotechnologyHealth Technology

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.

 Founder 2023-03-07
See the detail of Pieter H. Reitsma's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Pieter H. Reitsma's experience

Linked companies

Private companies1
Varmx BV
Logo Varmx BV

Varmx BV

BiotechnologyHealth Technology

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.

Health Technology

  1. Stock Market
  2. Insiders
  3. Pieter H. Reitsma